Star Combo Pharma Limited

FRC's fair value estimate for Star Combo Pharma Limited, and the rating behind it. S66.AX last traded at AUD 0.13, 48.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Star Combo Pharma Limited. Starting points for Star Combo Pharma Limited: P/E 48.3, beta 0.34 — an Household & Personal Products name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Star Combo Pharma Limited. Star Combo Pharma Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Star Combo Pharma Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Star Combo Pharma Limited. Star Combo Pharma Limited has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Star Combo Pharma Limited valued side by side against its closest peers. Star Combo Pharma Limited is measured against Household & Personal Products peers within the Consumer Defensive sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Star Combo Pharma Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Star Combo Pharma Limited executives and directors. Shares of Star Combo Pharma Limited have traded between AUD 0.11 and AUD 0.28 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Star Combo Pharma Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Star Combo Pharma Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Star Combo Pharma Limited. Coverage tracks Star Combo Pharma Limited within Household & Personal Products (Consumer Defensive). Press releases and market coverage, newest first.